Immuneering (IMRX) Projected to Release Quarterly Earnings on Wednesday

Key Points

• Immuneering is expected to report Q3 2026 results on November 11, with analysts forecasting a loss of $0.29 per share.
• In its previous quarter, the company posted a loss of $0.37 per share, missing the consensus estimate of a $0.31 loss.
• Analysts’ overall rating is “Moderate Buy,” with a consensus price target of $15.67, but HC Wainwright lowered its loss-per-share forecasts for 2026 and later years.

Immuneering (NASDAQ:IMRX - Get Free Report) is projected to issue its Q3 2026 resultson Wednesday, November 11th. Analysts expect the company to announce earnings of ($0.29) per share for the quarter. Investors can check the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, October 29, 2026 at 4:00 PM ET.

Immuneering (NASDAQ:IMRX - Get Free Report) last issued its quarterly earnings data on Thursday, October 29th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.06). On average, analysts expect Immuneering to post ($1.15) EPS for the current fiscal year and ($1.53) EPS for the next fiscal year.

Immuneering Stock Up 5.4%

Immuneering stock opened at $3.68 on Wednesday. Immuneering has a 52-week low of $3.38 and a 52-week high of $8.48. The firm has a market capitalization of $238.32 million, a price-to-earnings ratio of -3.57 and a beta of 0.49. The firm has a 50-day moving average price of $4.22 and a two-hundred day moving average price of $4.79.

Key Immuneering News

Here are the key news stories impacting Immuneering this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating, and Wall Street analysts collectively rate IMRX “Moderate Buy.” Immuneering Stock Rated Moderate Buy by Wall Street Analysts
• Negative Sentiment: HC Wainwright cut its loss-per-share forecasts across several periods. It lowered its Q4 2026 estimate to a loss of $0.39 from $0.32, and its fiscal 2026 estimate to a loss of $1.24 from $1.10. Forecast losses also increased for fiscal 2027–2030, including estimates of $1.78, $1.87, $1.86 and $0.81 per share, respectively. The more pessimistic outlook on future earnings could weigh on investor sentiment. Immuneering Corporation stock information

Wall Street Analyst Weigh In

IMRX has been the topic of a number of recent analyst reports. Mizuho set a $11.00 price target on Immuneering in a report on Thursday, October 29th. Needham & Company LLC boosted their price objective on Immuneering from $11.00 to $18.00 and gave the stock a "buy" rating in a research report on Monday, July 20th. Cantor Fitzgerald started coverage on Immuneering in a report on Wednesday, July 8th. They issued an "overweight" rating and a $17.00 price objective for the company. Chardan Capital upgraded Immuneering to a "strong-buy" rating in a research report on Monday, August 3rd. Finally, Wall Street Zen cut Immuneering from a "hold" rating to a "sell" rating in a research report on Monday, July 20th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Immuneering presently has an average rating of "Moderate Buy" and a consensus target price of $15.67.

Immuneering Company Profile

Immuneering Corporation is a clinical-stage biopharmaceutical company focused on developing medicines for cancer and other serious diseases. The company uses computational biology and drug-discovery technologies to identify therapeutic opportunities in complex biological pathways, with a particular emphasis on the RAS–RAF–MEK–ERK signaling pathway, which is frequently altered in cancer.

Immuneering's lead product candidate, IMM-1-104, is an orally administered pan-RAF inhibitor designed to provide deep and durable suppression of the MAP kinase pathway while potentially limiting treatment resistance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.